Non Small Cell Lung Cancer Nsclc clinical trials

Explore recruiting non small cell lung cancer nsclc clinical trials.

Recruiting non small cell lung cancer nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Small Cell Lung Cancer Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicenter single-arm phase II interventional study to evaluate the activity and safety of the combination of Platinum-Pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

Greece, Poland, Italy, Hungary, Germany, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)

Italy, Romania, Poland, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-blind Trial to Demonstrate Similar Efficacy, Safety, and Immunogenicity of FYB206 (Keytruda Biosimilar Candidate) in Comparison to Keytruda (Pembrolizumab) as an Add-on to Chemotherapy in Treatment-naïve Patients with Metastatic Non-squamous Non-small Cell Lung Cancer (LOTUS)

Romania, Bulgaria, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

C5751002 - A randomized, phase 3, open-label study to evaluate sigvotatug vedotin compared with docetaxel in adult participants with previously treated non-small cell lung cancer (Be6A Lung-01)

Norway, Belgium, Greece, Poland, Spain, Italy +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Non Small Cell Lung Cancer Nsclc trials by city

Non Small Cell Lung Cancer Nsclc in Toronto Non Small Cell Lung Cancer Nsclc in Vancouver Non Small Cell Lung Cancer Nsclc in Montreal Non Small Cell Lung Cancer Nsclc in Calgary Non Small Cell Lung Cancer Nsclc in Edmonton Non Small Cell Lung Cancer Nsclc in Ottawa Non Small Cell Lung Cancer Nsclc in Winnipeg Non Small Cell Lung Cancer Nsclc in Quebec City Non Small Cell Lung Cancer Nsclc in Hamilton Non Small Cell Lung Cancer Nsclc in Kitchener Non Small Cell Lung Cancer Nsclc in London Non Small Cell Lung Cancer Nsclc in Halifax Non Small Cell Lung Cancer Nsclc in New York Non Small Cell Lung Cancer Nsclc in Los Angeles Non Small Cell Lung Cancer Nsclc in Chicago Non Small Cell Lung Cancer Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease